Title:Implications of Nanoscale Based Drug Delivery Systems in Delivery and Targeting Tubulin Binding Agent, Noscapine in Cancer Cells
VOLUME: 13 ISSUE: 10
Author(s):Ramesh Chandra, Jitender Madan, Prashant Singh, Ankush Chandra, Pradeep Kumar, Vartika Tomar and Sujata K. Dass
Affiliation:Dr. B.R Ambedkar Centre for Biomedical Research, University of Delhi, Delhi-110007, India.
Keywords:Cancer, noscapine, 9-bromonoscapine, pharmacokinetic, drug delivery
Abstract:Noscapine, a tubulin binding anticancer agent undergoing Phase I/II clinical trials, inhibits tumor growth in nude mice bearing
human xenografts of breast, lung, ovarian, brain, and prostrate origin. The analogues of noscapine like 9-bromonoscapine (EM011) are 5
to 10-fold more active than parent compound, noscapine. Noscapinoids inhibit the proliferation of cancer cells that are resistant to
paclitaxel and epothilone. Noscapine also potentiated the anticancer activity of doxorubicin in a synergistic manner against triple negative
breast cancer (TNBC). However, physicochemical and pharmacokinetic (ED50~300-600 mg/kg bodyweight) limitations of noscapine
present hurdle in development of commercial anticancer formulations. Therefore, objectives of the present review are to summarize the
chemotherapeutic potential of noscapine and implications of nanoscale based drug delivery systems in enhancing the therapeutic efficacy
of noscapine in cancer cells. We have constructed noscapine-enveloped gelatin nanoparticles, NPs and poly (ethylene glycol) grafted
gelatin NPs as well as inclusion complex of noscapine in β-cyclodextrin (β-CD) and evaluated their physicochemical characteristics. The
Fe3O4 NPs were also used to incorporate noscapine in its polymeric nanomatrix system where molecular weight of the polymer governed
the encapsulation efficiency of drug. The enhanced noscapine delivery using μPAR-targeted optical-MR imaging trackable NPs offer a
great potential for image directed targeted delivery of noscapine. Human Serum Albumin NPs (150-300 nm) as efficient noscapine drug
delivery systems have also been developed for potential use in breast cancer.
